Imagion Biosystems announces an amendment to the previously announced close date. For the purposes of the Pro-Rata Renewable Rights Issue, the indicative close date is Friday, 15 November 2019.
Read the amendment.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)